Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Particip...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2007
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/26225
Acceso en línea:
https://doi.org/10.1016/j.ophtha.2006.12.028
https://repository.urosario.edu.co/handle/10336/26225
Palabra clave:
Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Diabetic Retinopathy
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Middle Aged
Ophthalmoscopy
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
Rights
License
Restringido (Acceso a grupos específicos)
id EDOCUR2_f3105e736a1fd4b6d7878700426a6ed9
oai_identifier_str oai:repository.urosario.edu.co:10336/26225
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
spelling 739ecf4c-3887-4668-bcea-2114906b5010-13cecefca-0c1e-48fa-8212-cf7c5afd7db0-15d691b1a-724b-4bf3-9f99-f0d80876ecb1-1e69e8b13-e9f7-4381-a9a8-95e96943618f-1e9382a84-7532-4238-a6e9-d0b1e9cc130f-1c4f0daa5-b76d-47f4-bec5-e92a853049b8-1390567f2-51a9-42ab-b5cb-bca59742d357-1653ad162-2458-4f09-9a0d-1ffc34f24a84-19f316ae0-f559-4a6e-a149-2ad535804452-12020-08-06T16:21:01Z2020-08-06T16:21:01Z2007-04Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventyeight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7 9.3 years were included in this analysisapplication/pdfhttps://doi.org/10.1016/j.ophtha.2006.12.028ISSN: 1549-4713EISSN: 0161-6420https://repository.urosario.edu.co/handle/10336/26225engElsevier750No. 4743OphthalmologyVol. 114Ophthalmology, ISSN: 15494713, 01616420, Vol.114, No.4 (April, 2007); pp.743-750https://www.aaojournal.org/article/S0161-6420(07)00018-8/fulltextRestringido (Acceso a grupos específicos)http://purl.org/coar/access_right/c_16ecOphthalmologyinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURAngiogenesis InhibitorsAntibodiesMonoclonalAntibodiesMonoclonalHumanizedBevacizumabDiabetic RetinopathyFemaleFluorescein AngiographyFollow-Up StudiesHumansInjectionsMacular EdemaMaleMiddle AgedOphthalmoscopyRetrospective StudiesTomographyOptical CoherenceTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityVitreous BodyPrimary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-upBevacizumab intravítreo primario (Avastin) para los resultados del edema macular diabético del Grupo de Estudio Panamericano de Colaboración Retina a los 6 meses de seguimientoarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Arevalo, J. FernandoFromow-Guerra, JansQuiroz-Mercado, HugoSanchez, Juan G.Wu, LihtehMaia, MauricioBerrocal, Maria H.Solis-Vivanco, AdrianaFarah, Michel E10336/26225oai:repository.urosario.edu.co:10336/262252021-06-03 00:50:28.898https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co
dc.title.spa.fl_str_mv Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
dc.title.TranslatedTitle.spa.fl_str_mv Bevacizumab intravítreo primario (Avastin) para los resultados del edema macular diabético del Grupo de Estudio Panamericano de Colaboración Retina a los 6 meses de seguimiento
title Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
spellingShingle Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Diabetic Retinopathy
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Middle Aged
Ophthalmoscopy
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
title_short Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
title_full Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
title_fullStr Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
title_full_unstemmed Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
title_sort Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up
dc.subject.keyword.spa.fl_str_mv Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Diabetic Retinopathy
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Middle Aged
Ophthalmoscopy
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
topic Angiogenesis Inhibitors
Antibodies
Monoclonal
Antibodies
Monoclonal
Humanized
Bevacizumab
Diabetic Retinopathy
Female
Fluorescein Angiography
Follow-Up Studies
Humans
Injections
Macular Edema
Male
Middle Aged
Ophthalmoscopy
Retrospective Studies
Tomography
Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity
Vitreous Body
description Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventyeight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7 9.3 years were included in this analysis
publishDate 2007
dc.date.created.spa.fl_str_mv 2007-04
dc.date.accessioned.none.fl_str_mv 2020-08-06T16:21:01Z
dc.date.available.none.fl_str_mv 2020-08-06T16:21:01Z
dc.type.eng.fl_str_mv article
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.spa.spa.fl_str_mv Artículo
dc.identifier.doi.none.fl_str_mv https://doi.org/10.1016/j.ophtha.2006.12.028
dc.identifier.issn.none.fl_str_mv ISSN: 1549-4713
EISSN: 0161-6420
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/26225
url https://doi.org/10.1016/j.ophtha.2006.12.028
https://repository.urosario.edu.co/handle/10336/26225
identifier_str_mv ISSN: 1549-4713
EISSN: 0161-6420
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.citationEndPage.none.fl_str_mv 750
dc.relation.citationIssue.none.fl_str_mv No. 4
dc.relation.citationStartPage.none.fl_str_mv 743
dc.relation.citationTitle.none.fl_str_mv Ophthalmology
dc.relation.citationVolume.none.fl_str_mv Vol. 114
dc.relation.ispartof.spa.fl_str_mv Ophthalmology, ISSN: 15494713, 01616420, Vol.114, No.4 (April, 2007); pp.743-750
dc.relation.uri.spa.fl_str_mv https://www.aaojournal.org/article/S0161-6420(07)00018-8/fulltext
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_16ec
dc.rights.acceso.spa.fl_str_mv Restringido (Acceso a grupos específicos)
rights_invalid_str_mv Restringido (Acceso a grupos específicos)
http://purl.org/coar/access_right/c_16ec
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Elsevier
dc.source.spa.fl_str_mv Ophthalmology
institution Universidad del Rosario
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167600376053760

Publicaciones similares